ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite this most of these tumors develop resistance to therapy due to specific gene mutations or alterations in gene expression. Understanding the mechanisms of resistance to Trastuzumab could be a useful tool in order t...

Full description

Bibliographic Details
Main Authors: Marco La Ferla, Francesca Lessi, Paolo Aretini, Davide Pellegrini, Sara Franceschi, Elena Tantillo, Michele Menicagli, Ivo Marchetti, Claudia Scopelliti, Prospero Civita, Claudia De Angelis, Lucrezia Diodati, Ilaria Bertolini, Manuela Roncella, Liam A. McDonnell, Jacob Hochman, Marzia Del Re, Cristian Scatena, Antonio G. Naccarato, Andrea Fontana, Chiara M. Mazzanti
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Oncology
Subjects:
Her2+ breast cancer
Trastuzumab resistance
ANKRD44
next generation sequencing
LC-MS/MS
gene silencing
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00547/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00547/full

Similar Items